Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mainz Biomed (MYNZ) Payables (2020 - 2025)

Mainz Biomed's Payables history spans 5 years, with the latest figure at $2.3 million for Q4 2024.

  • For Q4 2024, Payables fell 27.93% year-over-year to $2.3 million; the TTM value through Dec 2024 reached $2.3 million, down 27.93%, while the annual FY2024 figure was $2.3 million, 27.93% down from the prior year.
  • Payables for Q4 2024 was $2.3 million at Mainz Biomed, down from $3.2 million in the prior quarter.
  • Across five years, Payables topped out at $3.2 million in Q4 2023 and bottomed at $423664.0 in Q4 2020.
  • The 5-year median for Payables is $2.3 million (2024), against an average of $1.9 million.
  • The largest annual shift saw Payables surged 236.49% in 2022 before it fell 27.93% in 2024.
  • A 5-year view of Payables shows it stood at $423664.0 in 2020, then surged by 90.61% to $807540.0 in 2021, then soared by 236.49% to $2.7 million in 2022, then increased by 17.19% to $3.2 million in 2023, then fell by 27.93% to $2.3 million in 2024.
  • Per Business Quant, the three most recent readings for MYNZ's Payables are $2.3 million (Q4 2024), $3.2 million (Q4 2023), and $2.7 million (Q4 2022).